Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma

Diego Villa,1,* Eva Hoster,2,* Olivier Hermine,3 Wolfram Klapper,4 Michal Szymczyk,5 André Bosly,6 Michael Unterhalt,7 Lisa M. Rimsza,8 Colleen A. Ramsower,9 Ciara L. Freeman,9 David W. Scott,1 Alina S. Gerrie,1 Kerry J. Savage,1 Laurie H. Sehn,1 and Martin Dreyling7

1BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada; 2Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany; 3Hôpital Necker, Assistance Publique Hôpitaux de Paris, University of Paris Descartes, Paris, France; 4Department of Pathology, Hematopathology Section, University-Hospital Schleswig-Holstein, University of Kiel, Kiel, Germany; 5Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; 6Centre Hospitalier Universitaire – Université Catholique de Louvain Mont-Godin-Dinant, Yvoir, Belgium; 7Medizinische Klinik III, Ludwig-Maximilians-Universität München, Munich, Germany; 8Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ; and 9H. Lee Moffitt Cancer Centre & Research Institute and Morsani College of Medicine, University of South Florida, Tampa, FL

The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, cytarabine, cisplatin) in transplant-eligible patients with mantle cell lymphoma (MCL). A population-based cohort of 97 patients aged 18 to 65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Cancer. Baseline characteristics, response rates, and outcomes were compared with the cohort of 232 patients with MCL randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial. The primary endpoint was the hazard ratio (HR) of the progression-free survival (PFS) comparison between both groups, adjusted for MCL International Prognostic Index (MIPI), Ki67 index, and blastoid/pleomorphic morphology. Ann Arbor stage, lactate dehydrogenase, MIPI, blastoid morphology, and MCL35 assignments were similar between both groups. The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% of patients proceeded to autologous stem cell transplantation (ASCT) and 78% received maintenance rituximab (MR). The ORR to R-CHOP/R-DHAP was 94% (54% CR); 78% proceeded to ASCT and 2% received MR. There were no differences in PFS in unadjusted (HR, 0.87; 95% confidence interval [CI], 0.53-1.41; P = .56) or adjusted (HR, 0.79; 95% CI, 0.45-1.37; P = .40) comparisons. There were no clear differences in secondary endpoints in unadjusted or adjusted analyses. This retrospective adjusted comparison of 2 independent cohorts of younger patients with MCL suggests that R-B with ASCT and maintenance rituximab is a feasible and effective first-line treatment, with outcomes comparable to R-CHOP/R-DHAP with ASCT.

Key Points

- R-B with ASCT and MR is a feasible first-line strategy for younger, transplant-eligible patients with MCL.
- R-B with ASCT and MR achieves outcomes comparable to R-CHOP/R-DHAP with ASCT.
Introduction

The standard first-line therapy for mantle cell lymphoma (MCL) in young, fit patients incorporates rituximab (R) with cytotoxic chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) followed by maintenance rituximab (MR).1 The European MCL Younger trial showed that alternating R-CHOP (rituximab, cyclophosphamide, vincristine, and prednisone)/R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin) and ASCT is associated with a longer time to treatment failure (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.47-0.76) and overall survival (OS; HR, adjusted for MCL International Prognostic Index [MIPI] score, 0.74; 95% CI, 0.56-0.98) compared with R-CHOP and ASCT.2,3 Furthermore, the LyMa trial showed that 3 years of MR after 4 cycles of R-DHAP and ASCT is associated with improved progression-free survival (PFS) and OS compared with observation.4 MR can also be considered after ASCT consolidation following alternative induction regimens.5

Rituximab in combination with bendamustine (R-B) achieves higher response rates and PFS compared with R-CHOP in stem cell transplant-ineligible patients with less toxicity.6,7 In transplant-eligible patients, R-B achieves response rates, ASCT rates, and outcomes that are comparable to those historically achieved with R-CHOP. In that study, patients consistently received 2 years of MR after ASCT.8

The Southwest Oncology Group 1106 randomized clinical trial compared R-B against R-Hyper-CVAD (hyperfractionated rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone, methotrexate, cytarabine) before ASCT. Although the study was terminated early because of higher toxicity and lower rates of stem cell mobilization in the R-Hyper-CVAD arm, response rates, minimal residual disease (MRD) negativity, and outcomes were favorable and similar between both regimens (5-year PFS: 66% R-B vs 62% R-Hyper-CVAD; 5-year OS: 80% R-B vs 74% R-Hyper-CVAD).9 Collectively, these data support that use of R-B should be further explored in the transplant-eligible population.

R-B can be administered in the outpatient setting with less toxicity than R-CHOP/R-DHAP or R-Hyper-CVAD. However, R-B has never been compared with R-CHOP/R-DHAP as induction therapy before ASCT. The objective of this study was to explore differences in outcomes achieved using first-line R-B followed by ASCT and R maintenance in a real-world cohort from British Columbia (BC), Canada, against the R-CHOP/R-DHAP+ASCT arm of the randomized European MCL Younger trial in a retrospective, adjusted pooled individual patient data analysis.

Methods

R-B cohort

Patients aged 18 to 65 years with stage II to IV MCL who were randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial and included in the primary analysis during July 2004 to March 2010 were identified. Patients were planned to receive a total of 6 cycles of chemotherapy including 3 of R-CHOP alternating with 3 of R-DHAP followed by high-dose cytarabine-containing chemotherapy and total body irradiation conditioning and ASCT. MR after ASCT was not recommended in this study as it was not yet standard of care. Patients were followed every 3 months until progression, and CT scans were performed every 6 months.2

Response assessment

In both cohorts, response after 6 cycles of first-line induction therapy was evaluated with CT scans, with or without bone marrow biopsies, and assessed using the 1999 International Working Group criteria.11 Cases with radiologic unconfirmed complete response in whom bone marrow biopsy for response assessment was not performed or available were conservatively downgraded to a partial response. In the R-B cohort, these criteria were centrally and retrospectively applied exclusively for purposes of the current analysis, whereas in the R-CHOP/R-DHAP cohort, these criteria were applied by local investigators during the course of the trial. Positron emission tomography scans or gastrointestinal biopsies were not routinely performed in either cohort. MRD assessments were not performed in the R-B cohort.

Gene expression profiling (MCL35 assay)

At baseline, diagnostic formalin-fixed paraffin-embedded tumor samples, when available from both cohorts, were extracted for the MCL35 assay. After extraction, gene expression was quantified from 200 ng RNA on the NanoString platform (NanoString Technologies, Seattle, WA), with a predefined code set interrogating for expression of 17 proliferation genes and 18 housekeeping genes (MCL35 assay), using the “high sensitivity” setting of the second-generation nCounter Prep Station and 490 fields of view. Normalization for Oncology Group (ECOG) performance status 3 to 4, pregnancy or lactation, or severely impaired cardiac, pulmonary, hepatic (transaminases > 3 times upper limits of normal or total bilirubin > 34.2 μmol/L), or renal (creatinine > 2 times upper limit of normal) function, unless related to lymphoma, were excluded.2

In BC, 6 cycles of R-B have been recommended as first-line therapy for all patients with MCL regardless of age or fitness since June 2013. Transplant-eligible patients responding to R-B proceed to high-dose BEAM (carmustine, etoposide, cytarabine, and melphalan) and ASCT. MR, administered every 3 months for 2 years, is also recommended for responding patients after ASCT.8

Patients underwent response assessment after completion of induction therapy and after ASCT, generally with computed tomography (CT) scans with or without bone marrow biopsies. During MR, patients were assessed before each scheduled dose. Following completion of MR, patients were assessed according to physician discretion, generally every 3 to 6 months, with no specific guidelines indicating frequency of follow-up or imaging investigations, particularly in asymptomatic patients without clinical concern for relapse or progression.

R-CHOP/R-DHAP cohort

Patients aged 18 to 65 years with stage II to IV MCL who were randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial and included in the primary analysis during July 2004 to March 2010 were identified. Patients were planned to receive a total of 6 cycles of chemotherapy including 3 of R-CHOP alternating with 3 of R-DHAP followed by high-dose cytarabine-containing chemotherapy and total body irradiation conditioning and ASCT. MR after ASCT was not recommended in this study as it was not yet standard of care. Patients were followed every 3 months until progression, and CT scans were performed every 6 months.2
RNA loading was performed using the geometric mean of 18 housekeeping genes, and if this was below a predefined threshold, the assay was deemed to have failed.\textsuperscript{12-15}

**Statistical analysis**

Characteristics between cohorts were compared using descriptive statistics. Survival outcomes were summarized using the Kaplan-Meier method, and differences between groups were exploratively compared using the log-rank test. Multivariate Cox models were fitted to evaluate the effect of treatment strategy between cohorts, adjusted for relevant prognostic factors.

The primary end point was PFS with the HR of the comparison between both groups, adjusted for MIPI score as a continuous variable, Ki67 index (\( \geq 30\% \) vs \(< 30\% \)), and blastoid/pleomorphic morphology as the primary effect measure. Additional analyses were performed evaluating the HR adjusted for each of the following single variables: MIPI score as a continuous variable, individual MIPI variables, Ki-67 index, and blastoid/pleomorphic morphology. The adjusted HR was also evaluated for combinations of these variables. MCL35 results were not included in the multivariate models because of incomplete data.

PFS was calculated from the initiation of first-line therapy to date of first progression/relapse, with censoring at date of last remission for patients without progression/relapse or date of next lymphoma therapy initiation for patients without preceding progression/relapse. Secondary end points included response rates, ASCT rates, event-free survival (EFS), OS, and time to next treatment (TTNT). EFS was calculated from the date of start of first-line therapy to date of first progression/relapse, date of next lymphoma therapy (independent of progression/treatment failure), or date of death from any cause. OS was calculated from the date of start of first-line therapy to the date of death from any cause. Follow-up was calculated by the reverse Kaplan-Meier method. In this analysis, patients with PFS, EFS, or OS events were censored for observation time due to their event. Patients without an event were counted as events at end of observation. Analyses were performed using SPSS 14 and IBM SPSS Statistics Subscription (11-2018).

TTNT was calculated from the date of start of first-line therapy to the date of start of the next line of therapy. TTNT was estimated using competing risk analysis, treating death without next line of treatment as a competing event. TTNT analyses were performed using the cmprsk package of The R Project for Statistical Computing, version 4.0.3. Studies were approved by their governing Research Ethics Boards. The studies were conducted according to the Declaration of Helsinki.

![Figure 1. Patient identification.](image-url)
Results

Baseline characteristics

A total of 139 patients 18 to 65 years of age were diagnosed with MCL in BC between June 2013 and January 2020. Of these, 16 were treated with non R-B regimens, most commonly R-CHOP/R-DHAP or R-CHOP according to physician discretion. Thirteen patients did not meet MCL Younger trial eligibility and were excluded. Additionally, 4 patients who received R-B before June 2013 were identified and included in this analysis. A total of 97 patients who received R-B were included (Figure 1). The 232 patients with MCL treated with R-CHOP/R-DHAP in the primary analysis of the MCL Younger trial were included.

Ann Arbor stage, lactate dehydrogenase ratio to the upper limit of normal, MCL35 risk groups, and blastoid/pleomorphic morphology were similar between both groups. Patients treated with R-B were older, had slightly worse performance status, had a greater proportion with Ki67 ≥ 30%, and showed a trend toward higher MIPI risk (Table 1). Immunohistochemical or molecular testing for TP53 alterations was not performed.

 Archived formalin-fixed paraffin-embedded tissue from diagnosis was available and retrieved from N = 50 and N = 36 patients from the real-world and trial cohorts, respectively. There were no differences in MCL35 risk groups between cohorts, although note is made of the >2:1 difference in retrieved material between these cohorts.

Response rates and outcomes

The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% patients proceeded to ASCT, and 78% received maintenance rituximab (MR). The ORR to R-CHOP/R-DHAP

Table 1. Baseline characteristics

| Characteristic                        | R-B (n = 97) | R-CHOP/R-DHAP (n = 232) | P   |
|---------------------------------------|-------------|-------------------------|-----|
| Median year (range)                   | 2016 (2012-2020) | 2007 (2004-2010)       | <.001 |
| Age, y                                | 58 (40-65)  | 56 (32-65)              | <.001 |
| Age ≥ 60, n (%)                       | 42 (43)     | 64 (27)                 | .004 |
| Male sex, n (%)                       | 60 (62)     | 183 (79)                | .001 |
| Ann Arbor stage, n (%)                |             |                         | .17  |
| II                                    | 4 (4)       | 10 (4)                  |     |
| III                                   | 6 (6)       | 31 (13)                 |     |
| IV                                    | 87 (90)     | 191 (82)                |     |
| Bone marrow involvement, n (%)        | 76 (78)     | 173 (75)                | .47  |
| B symptoms, n (%)                     | 11/78 (14)  | 71 (31)                 | .004 |
| ECOG performance status, n (%)        |             |                         | <.001 |
| 0                                     | 30 (31)     | 150 (65)                |     |
| 1                                     | 54 (56)     | 73 (32)                 |     |
| 2                                     | 13 (13)     | 9 (4)                   |     |
| Lactate dehydrogenase                 |             |                         |     |
| Lactate dehydrogenase/upper limits of normal ratio (range) | 0.81 (0.41-3.26) | 0.89 (0.41-12.2) | .30  |
| Elevated, n (%)                       | 27 (28)     | 81 (35)                 | .21  |
| WBC count × 10⁹/L (range)             | 7.0 (3.1-136) | 7.6 (1.1-323.8)        | .34  |
| MIPI                                  |             |                         |     |
| MIPI score (range)                    | 5.65 (4.58-7.82) | 5.56 (4.07-8.68)       | .089 |
| MIPI risk category, n(%)              |             |                         | .16  |
| Low risk                              | 53 (55)     | 150 (65)                |     |
| Intermediate risk                     | 24 (25)     | 51 (22)                 |     |
| High risk                             | 20 (21)     | 31 (13)                 |     |
| Blastoid/pleomorphic, n (%)           | 7 (7)       | 14/169 (8)              | .76  |
| KI67 index                            |             |                         |     |
| Median (range)                        | 25 (5-90)   | 21 (1.5-95)             | .14  |
| ≥30%, n (%)                           | 40/89 (45)  | 34/129 (26)             | .004 |
| MCL35 risk group, n (%)               |             |                         | .60  |
| Low risk                              | 27/50 (54)  | 21/36 (58)              |     |
| Standard risk                         | 17/50 (34)  | 13/36 (38)              |     |
| High risk                             | 6/50 (12)   | 2/36 (6)                |     |
was 94% (54% CR, including CR unconfirmed); 78% proceeded to ASCT, and 2% received MR (Figure 1; Table 2). In the 12 patients on R-B who did not proceed with ASCT for reasons other than stable disease/progressive disease, reasons were patient preference (n = 11) and physician decision based on toxicity of R-B (n = 1). There were no cases with failure to mobilize stem cells after R-B. Conversely, 18 of 36 responding patients who did not proceed with ASCT after R-CHOP/R-DHAP had insufficient stem cell mobilization. The other more frequent reasons were patient choice (n = 6) and toxicity of induction chemotherapy (n = 5).

After a median follow-up of 4.3 years (range, 0.2-7.6 years) in the R-B group and 7.1 years (range, 0.1-14.8 years) in the R-CHOP/R-DHAP group, there were no differences in PFS between both groups in an unadjusted analysis (5-year rate, 76% vs 68%, respectively; HR, 0.87; 95% CI, 0.53-1.41; P = .56; Figure 2A). Similarly, the PFS HR for the comparison of R-B vs R-CHOP/R-DHAP adjusted for MIPI, Ki67 ≥ 30%, and blastoid/pleomorphic morphology was 0.79 (95% CI, 0.45-1.37; P = .40). The HRs were below 1 but far from statistical significance in models adjusting the treatment comparison for MIPI score, individual MIPI variables, Ki67, or blastoid/pleomorphic morphology individually or in combinations (Table 3).

There were no clear differences in EFS in unadjusted (5-year rate, 70% vs 65%; HR, 0.88; 95% CI, 0.56-1.37; P = .57; Figure 2B).

Table 2. Response rates, additional therapies after induction, and subsequent outcomes

| Response rates and additional first line therapies | R-B        | R-CHOP/R-DHAP | P   |
|---------------------------------------------------|------------|--------------|-----|
| Response rates after induction, n (%)             | N = 97     | N = 232      |     |
| Complete response                                 | 52 (54)    | 122/226* (54) |     |
| Partial response                                  | 35 (36)    | 91/226 (40)  |     |
| Stable disease                                    | 2 (2)      | 5/226 (2)    |     |
| Progressive disease                               | 8 (8)      | 8/226 (4)    |     |
| ASCT, n (%)                                       | 75 (77)    | 181 (78)     | .890|
| Maintenance rituximab, n (%)                      | 76 (78)    | 4 (2)        | <.001|

| Time-to-event outcomes from start of induction     | N = 97     | N = 232      |     |
|---------------------------------------------------|------------|--------------|-----|
| PFS from start of induction                        | NR†        | 9.5 (6.5-12.6) | .564|
| 5-y rate (95% CI)                                  | 76% (58-94)| 68% (62-74)  |     |
| EFS from start of induction                        | NR†        | 7.9 (5.9-10) | .570|
| 5-y rate (95% CI)                                  | 70% (51-89)| 65% (59-71)  |     |
| OS from start of induction                         | NR†        | 13.8 (9.5-18.1)| .443|
| 5-y rate (95% CI)                                  | 79% (64-94)| 77% (72-82)  |     |
| TTNT from start of induction                       | NR†        | NR           | .918|
| 5-y rate (95% CI)                                  | 24% (14-36)| 27% (21-33)  |     |

| Time-to-event outcomes from ASCT                   | N = 75     | N = 181      |     |
|---------------------------------------------------|------------|--------------|-----|
| PFS from ASCT                                     | NR†        | NR           | .095|
| 5-y rate (95% CI)                                  | 87% (63-100)| 75% (68-82)  |     |
| EFS from ASCT                                     | NR†        | 9.4 (6.9-11.9)| .342|
| 5-y rate (95% CI)                                  | 79% (56-100)| 73% (66-80)  |     |
| OS from ASCT                                      | NR†        | 13.4 (7.2-19.6)| .137|
| 5-y rate (95% CI)                                  | 88% (74-100)| 80% (74-86)  |     |
| TTNT from ASCT                                    | NR†        | NR           | .373|
| 5-y rate (95% CI)                                  | 14% (0-35) | 20% (13-26)  |     |

*S Six patients excluded: induction treatment aborted without restaging.
†Median outcomes not reached in the R-B group because of insufficient duration of follow-up.
Figure 2. Crude outcome comparisons between R-B and R-CHOP/R-DHAP. (A) PFS. (B) EFS. (C) OS.
Table 3. Crude and adjusted PFS, EFS, and OS comparisons between R-B and R-CHOP/R-DHAP

| Variable(s) in the model | Unadjusted analyses | Adjusted analyses |
|--------------------------|---------------------|------------------|
|                         | R-B | R-CHOP/R-DHAP | HR (95% CI) | P         | R-B | R-CHOP/R-DHAP | HR (95% CI) | P     | R-B | R-CHOP/R-DHAP | HR (95% CI) | P     |
| R-B vs R-CHOP/R-DHAP     | 97  | 232       | 0.87 (0.53-1.41) | .56       | 0.88 (0.56-1.37) | .57       | 0.81 (0.46-1.40) | .44 |
| MIPI continuous R-B      | 97  | N/A       | 3.65 (1.94-6.85) | <.001    | 3.26 (1.78-5.96) | <.001    | 3.94 (2.0-7.76) | <.001 |
| MIPI continuous R-CHOP/R-DHAP | N/A | 232   | 1.78 (1.31-2.42) | <.001    | 1.92 (1.46-2.52) | <.001    | 2.33 (1.72-3.15) | <.001 |
| Blastoid/pleomorphic vs not R-B | 97 | N/A | 4.16 (1.39-12.47) | .011    | 3.5 (1.19-10.27) | .023    | 3.75 (1.07-13.21) | .039 |
| Blastoid/pleomorphic vs not R-CHOP/R-DHAP | N/A | 169 | 1.63 (0.78-3.34) | .196    | 1.72 (0.88-3.35) | .110    | 1.73 (0.78-3.83) | .174 |
| Ki67 ≥ 30% vs < 30% R-B | 89  | N/A       | 2.08 (0.85-5.1) | .110     | 2.6 (1.1-6.15) | .029     | 2.27 (0.76-6.76) | .143 |
| Ki67 ≥ 30% vs < 30% R-CHOP/R-DHAP | N/A | 129 | 1.88 (1.03-3.44) | .042    | 2.24 (1.31-3.83) | .003    | 2.86 (1.55-5.29) | .001 |
| MCL35 high risk vs not R-B | 50  | N/A       | 2.42 (0.67-7.87) | .180    | 2.14 (0.6-7.6) | .240    | 6.65 (1.57-28.2) | .010 |
| MCL35 high risk vs not R-CHOP/R-DHAP | N/A | 36   | 20.5 (2.81-149) | .003    | 21 (2.89-153) | .003    | 20.5 (2.81-149) | .003 |

N/A, not applicable.

or adjusted analyses (HR, 0.75; 95% CI, 0.45-1.25; P = .27). There were no differences in OS in unadjusted (5-year rate, 79% vs 77%; HR, 0.81; 95% CI, 0.46-1.40; P = .44; Figure 2C) or adjusted analyses (HR, 0.65; 95% CI, 0.24-1.24; P = .19). The HRs were also below 1 and far from statistical significance in the various adjusted models (Table 3). Outcomes calculated from the point of ASCT (R-B, n = 75; R-CHOP/R-DHAP, n = 181) were also similar between both cohorts (Table 2).

There were 16 (15%) deaths in the R-B cohort: 12 from lymphoma progression, 3 from secondary neoplasia, and 1 unrelated. There were no treatment-related deaths. There were 93 (40%) deaths in the R-CHOP/R-DHAP cohort: 38 from lymphoma progression, 15 during/after salvage treatment, 9 ASCT related, 2 cardiac deaths in first remission, 11 secondary neoplasia, 11 unclear cause, and 7 unrelated.

**TTNT**

TTNT was also similar in unadjusted analyses (5-year rate, 24% vs 27%; HR, 1.01; 95% CI, 0.62-1.67; P = .918; Figure 3). Next treatments were diverse, with more frequent use of ibritinib after R-B but more frequent rituximab-based chemotherapy after R-CHOP/R-DHAP (Table 4). About 15% in each group received allogeneic stem cell transplantation.

**Discussion**

In this retrospective comparison of 2 independent cohorts of younger patients with MCL, there were no marked differences in any measure of outcome between first-line R-B with ASCT and MR compared with R-CHOP/R-DHAP with ASCT and observation. Outcomes in the R-B cohort were favorable, including 5-year PFS of
It is possible low- or intermediate-risk patients morphic morphology are associated with higher rates of progressive care practices between treatment eras, patient selection for ASCT between a single transplant center in BC vs multiple centers in Europe, and use of different high-dose regimens especially the total body irradiation-containing regimen used in the MCL Younger trial. The differential use of MR between cohorts may also have influenced outcomes. The LyMa trial showed that 3 years of MR after 4 cycles of R-DHAP and ASCT is associated with improved PFS and OS compared with observation. Conversely, a subgroup analysis of the MAINTAIN trial suggests that 2 years of MR was not associated with improved PFS or OS after 6 cycles of R-B in transplant-ineligible patients. In contrast, large retrospective real-world analyses revealed an improved PFS and OS after R-B followed by MR. Our data cannot determine whether the use of MR compensated in the long term for the lack of high-dose cytarabine induction and consolidation in patients treated with R-B plus high-dose BEAM and ASCT. Furthermore, 9 of 22 (41%) patients who did not undergo ASCT after R-B received MR, whereas 2 of 51 (4%) who did not undergo ASCT after R-CHOP/R-DHAP received MR. This imbalance may also have improved outcomes in the R-B cohort, although these numbers are small.

### Table 4. Next-second-line therapies

| Individual treatments | R-B (n = 21) | R-CHOP/R-DHAP (n = 75) |
|-----------------------|-------------|-----------------------|
| **Cytarabine based**  |             |                       |
| R-high-dose cytarabine| 0           | 11 (15)               |
| R-DHAP                | 1 (5)       | 9 (12)                |
| DEXA-BEAM             | 0           | 5 (7)                 |
| R-Hyper-CVAD          | 0           | 2 (3)                 |
| R-B                   | 0           | 12 (16)               |
| R-FC                  | 0           | 8 (11)*               |
| BTK inhibitor         | 11 (52)     | 2 (3)                 |
| R-CHOP                | 7 (33)      | 1 (1)                 |
| Bortezomib-based      | 0           | 5 (7)                 |
| Radiation alone       | 0           | 4 (5)                 |
| Temsirolimus          | 0           | 3 (4)                 |
| Other                 | 2 (10)†     | 10 (13)#              |
| Unknown               | 0           | 3 (4)                 |
| **Stem cell transplantation** |         |                       |
| Autologous            | 3 (14)      | 11 (15)               |
| Autologous            | 0           | 5 (7)§                |

DEXA-BEAM, desamethasone, carmustine, etoposide, cytarabine, melphalan.
*Includes 2 patients who also received mitoxantrone.
†One R-GDP and 1 HDMTX.
‡Other: 3 R-ICE, 3 directly to stem cell transplant, 1 intrathelial chemotherapy, 1 rituximab monotherapy, and 1 MCL-002 trial.
§None had previously received ASCT as consolidation after R-CHOP/R-DHAP.
Various randomized studies in MCL will evaluate the impact of the addition of novel agents, particularly Bruton tyrosine kinase inhibitors (BTKis), into front-line immunochemotherapy for MCL. The Triangle study (#NCT 02858258) will evaluate the addition of ibrutinib in transplant-eligible patients receiving R-CHOP/R-DHAP and whether ASCT is still justified in these patients. The ECOG/American College of Radiology Imaging Network 4181 study (#NCT 04115631) will evaluate the addition of acalabrutinib in transplant-eligible patients receiving R-B induction with or without cytarabine. Two randomized phase 3 trials (#NCT 01776840 and #NCT 02972840) will evaluate the addition of BTKis in transplant-ineligible patients receiving R-B and MR. Toxicity and efficacy will inform the optimal immunochemotherapy backbone if BTKis are eventually brought into the front-line setting.

In summary, there were no differences in unadjusted or adjusted outcomes between R-B with ASCT and MR vs R-CHOP/R-DHAP with ASCT and observation in this retrospective comparison of 2 independent cohorts of transplant-eligible patients with MCL. R-B with ASCT and MR may be a reasonable first-line strategy for younger, transplant-eligible patients with MCL.

Acknowledgments

Medical writers were not involved in the writing of this manuscript.

This study was funded by National Cancer Institute grant CA217847.

Authorship

Contribution: D.V., E.H., and M.D. designed the research; D.V. and E.H. performed the research and analyzed data; and all authors contributed to the acquisition, analysis, or interpretation of data for this article and drafts of this article, revised the manuscript critically for important intellectual content, approved the final version to be published, and agreed to be accountable for all aspects of the article.

Conflict-of-interest disclosure: D.V. received honoraria/consulting fees from Janssen, Roche, BMS, Celgene, Kite/Gilead, AstraZeneca, Abbvie, Kyowa Kirin, and BeiGene and research funding (to the institution) from Roche and AstraZeneca. K.J.S. received honoraria/consulting fees from BMS, Seattle Genetics, Kyowa, AstraZeneca, Merck, Gilead, Novartis, Janssen, and DSMC Regeneron and was on the steering committee for Beigene. D.W.S. received consultancy fees from Abbvie, AstraZeneca, Celgene, Incyte, and Janssen and research funding from Janssen, NanoString Technologies, and Roche. D.W.S., C.A.R., and L.M.R. are named inventors on a patent for the MCL35 assay. A.S.G. received research funding from Roche, AstraZeneca, Abbvie, and Janssen and honoraria/consulting fees from Sandoz, AstraZeneca, Abbvie, and Janssen. C.L.F. received honoraria/consulting fees from BMS, Seattle Genetics, Celgene, Abbvie, Sanofi, Incyte, Amgen, and Janssen and research funding from Teva, Janssen, and Roche/Genentech. The remaining authors declare no competing financial interests.

ORCID profiles: D.V., 0000-0002-4625-3009; E.H., 0000-0002-0749-1389; W.K., 0000-0001-7208-4117; D.W.S., 0000-0002-0435-5947; A.S.G., 0000-0003-4727-1425; K.J.S., 0000-0002-5835-9863; M.D., 0000-0002-0358-5249.

Correspondence: Diego Villa, BC Cancer–Vancouver Cancer Centre, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada; e-mail: dvilla@bccancer.bc.ca.

References

1. Dreyling M, Campo E, Hermine O, et al; ESMO Guidelines Committee. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv62-iv71.

2. Hermine O, Hoster E, Walewski J, et al; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565-575.

3. Hermine O, Jiang L, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a long-term follow-up of the randomized, open-label, phase 3 trial of the european mantle cell lymphoma Network [abstract]. Blood. 2021;138(suppl 1). Abstract 380.

4. Le Gouill S, Thieblemont C, Oberic L, et al; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250-1260.

5. Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647-1656.

6. Rummel MJ, Niederle N, Maschmeyer G, et al; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.

7. Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984-991.

8. Villa D, Sehn LH, Savage KJ, et al. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2019;3(20):3132-3135.

9. Kamdar M, Li H, Chen RW, et al. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv. 2019;3(20):3132-3135.

10. Abrigueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28(10):2489-2495.
11. Cheson BD, Horning SJ, Coiffrer B, et al; NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17(4):1244.

12. Ramsower CA, Maguire A, Robetorye RS, et al. Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. J Hematop. 2020;13(4):231-238.

13. Rauert-Wunderlich H, Mottok A, Scott DW, et al. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. Br J Haematol. 2019;184(4):616-624.

14. Rosenthal AC, Ramsower CA, Mwangi R, et al. Clinical validation of MCL35 in mantle cell lymphoma patients ≥65 years receiving bendamustine-rituximab [abstract]. Blood. 2021;138(suppl 1). Abstract 3517.

15. Scott DW, Abrisqueta P, Wright GW, et al; Lymphoma/Leukemia Molecular Profiling Project. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35(15):1668-1677.

16. Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410-418.

17. Kolstad A, Laurell A, Jerkeman M, et al. Nordic Lymphoma Group. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123(19):2953-2959.

18. Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(suppl 15):7503.

19. Martin P, Wang M, Kumar A, et al. Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice. J Clin Oncol. 2021;39(suppl 15):7504.

20. Hill BT, Switchenko JM, Martin P, et al. Maintenance rituximab improves outcomes in mantle cell lymphoma patients who respond to induction therapy with bendamustine + rituximab without autologous transplant [abstract]. Blood. 2019;134(suppl 1). Abstract 1525.